{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:16:41Z","timestamp":1648865801984},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.leukres.2011.05.032","type":"journal-article","created":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T21:10:14Z","timestamp":1309122614000},"page":"1611-1615","source":"Crossref","is-referenced-by-count":5,"title":["Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations"],"prefix":"10.1016","volume":"35","author":[{"given":"Harshabad","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Asali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian L.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen K.","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Amrein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilene","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal C.","family":"Attar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.05.032_bib0005","unstructured":"Altekruse S, Kosary C, Krapcho M, Neyman M, et al. SEER incidence and NCHS mortality statistics. SEER Cancer Statistics Review, 1975\u20132007; 2010."},{"key":"10.1016\/j.leukres.2011.05.032_bib0010","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2011.05.032_bib0015","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0025","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Frohling","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461","volume":"108","author":"Farag","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0035","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.05.032_bib0040","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2010-01-262543","article-title":"Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"116","author":"Becker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0045","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","article-title":"Structural and functional alterations of FLT3 in acute myeloid leukemia","volume":"15","author":"Meshinchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.032_bib0050","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Frohling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0055","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0060","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ajh.21458","article-title":"FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype","volume":"84","author":"Ferrara","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.05.032_bib0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-0609.2004.00225.x","article-title":"Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients","volume":"72","author":"Andersson","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2011.05.032_bib0070","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","article-title":"FLT3 RAS, and TP53 mutations in elderly patients with acute myeloid leukemia","volume":"97","author":"Stirewalt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0075","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2010-05-283648","article-title":"FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"116","author":"Whitman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/10428190801947567","article-title":"Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients","volume":"49","author":"Breccia","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2011.05.032_bib0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2003.09.016","article-title":"FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype","volume":"28","author":"Beran","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.032_bib0090","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2003-07-2441","article-title":"FLT3 mutations in childhood acute lymphoblastic leukemia","volume":"103","author":"Armstrong","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0095","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.05.032_bib0100","first-page":"19","article-title":"Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia","volume":"88","author":"Moreno","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.05.032_bib0105","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2004-06-2459","article-title":"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)","volume":"105","author":"Bagrintseva","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.032_bib0110","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.critrevonc.2003.04.007","article-title":"Acute myeloid leukemia in the older patient","volume":"48","author":"Godwin","year":"2003","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611002670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611002670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T16:26:21Z","timestamp":1543681581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611002670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0145212611002670"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.05.032","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}